Lung Cancer

Lung Cancer

KRAS G12C Mutation with Dr Tetsuya Mitsudomi

This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. 

No One Missed - Non-Small Cell Lung Cancer Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate individualized...

Breakthrough Therapies - ALK with Dr Ignatius Ou

Dr Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. 


RET Fusions in Lung Cancer with Dr Alex Drilon

Dr Alex Drilon discusses his career and work on RET fusions in lung cancer.

WCLC 2020 Highlights and Wrap-Up

Together Dr Liu, Dr Duma and Dr Soo discuss key science, highlights, benefits and challenges of the virtual meeting.

Target Therapies for Lung Cancer

Listen as Dr Matt-Amaral shares her insights into novel strategies that are evolving with genetic driver mutations and how immunotherapy is changing the way we treat metastatic disease patients.

Single-Fraction Stereotactic Body Radiation Therapy Effective for Early Stage Lung Cancer

Dr Gregory Videtic, radiation oncologist at Cleveland Clinic Cancer Center, joins the Cancer Advances podcast to discuss the findings that were presented at the American Society for Radiation Oncology annual meeting.

ESMO Open - Immune Checkpoint Inhibitors for Every Non-Small Cell Lung Cancer Patient

Here, non-small cell lung cancer has to be categorized first according to the presence of activating mutations and second according to the programmed cell death ligand 1 expression.

ESMO Open - Immunotherapy in Lung Cancer

This podcast gives an overview on the current evidence of immune checkpoint inhibitors in patients with non-small cell lung cancer.

Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer

Multiple experts in the field discuss the role of acquired resistance mutations in first-line treatment selection, the potential for CNS disease, and the efficacy and safety of novel treatment options for patients with ALK+ advanced NSCLC.

KRAS Mutations - Non-Small Cell Lung Cancer

Dr Stephen Liu discusses the data presentation from ASCO20 Virtual Scientific Program, Abstract 9544/Poster 310: Characterization of KRAS mutations in non-small cell lung cancer.


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)